Mary Kay Bader, Distinguished Leader in Neuroscience Nursing, Joins Cerebrotech’s Scientific Advisory Board
Pleasanton, CA, November 19, 2015 --(PR.com
)-- Cerebrotech Medical Systems of Pleasanton, California, today announced that Mary Kay Bader, RN, MSN, CCNS, FAHA, FNCS, renowned Critical Care Nurse Specialist and educator, has joined the company’s Scientific Advisory Board (SAB). Ms. Bader is a prominent leader in neurologic intensive care, and currently serves as the Neuro/ICU Clinical Nurse Specialist at Mission Hospital in Mission Viejo, California. She is a notable advocate of collaborative multidisciplinary approaches to improve medical outcomes for cardiac arrest survivors and patients with stroke, traumatic brain injury and other neurologic trauma. Ms. Bader has authored 37 scholarly articles and co-edited 3 books; she is a national lecturer on topics impacting neurocritical care, such as multimodality monitoring, targeted temperature management, and others. Ms. Bader’s extensive resume includes prior and current appointments to key leadership posts of several professional organizations.
“We are delighted to welcome yet another extraordinary clinician, researcher and patient care advocate to the ranks of our scientific advisors,” said Mitch Levinson, Cerebrotech’s CEO. “Our company’s mission is to improve management of patients with brain injuries by providing early warning of potentially lethal or debilitating events, such as worsening swelling and bleeding. The addition of Mary Kay Bader to the SAB, who is a very well known and highly respected member of the neurocritical care community, underscores Cerebrotech’s commitment to meeting the needs of patients, physicians, nurses, and other healthcare professionals as we work to commercialize our ground-breaking technology.”
“Cerebrotech has made tremendous progress in the development of its promising device during the past several years,” added Dr. Wade Smith, chairman of the company’s advisory board. “Mary Kay’s great enthusiasm, extensive experience with novel neuromonitoring systems, and her keen understanding of the ICU environment will be invaluable to Cerebrotech’s continued success.”
Ms. Bader becomes the sixth member of Cerebrotech’s SAB, joining board chairman Wade Smith MD, PhD (Daryl R. Gress Endowed Professor of Neurocritical Care and Stroke at the University of California, San Francisco), Peter Le Roux, MD, FACS (Professor of Neurosurgery at the Sidney Kimmel Medical College, Thomas Jefferson University), Nathan Selden, MD, PhD, FACS, FAAP (Campagna Chair of Pediatric Neurosurgery at the Oregon Health & Science University), Jose Suarez, MD (Head of Vascular Neurology and Neurocritical Care at the Baylor College of Medicine), and Gene Sung, MD (Chief of the Division of Stroke and Neurocritical Care at the University of Southern California).
About Cerebrotech Medical Systems:
Cerebrotech Medical Systems, Inc., was founded in late 2010 with the mission to provide clinicians with a completely non-invasive monitor for early detection of cerebral events that can be catastrophic for patients after stroke, traumatic brain injury, brain surgery and other conditions. With earlier detection, physicians can intervene sooner, saving lives and improving outcomes, while reducing hospital costs. The company’s core intellectual property is licensed exclusively from the University of California at Berkeley. Cerebrotech is a venture capital-backed medical device company located in Pleasanton, CA. More information about Cerebrotech can be found at www.cerebrotechmedical.com